NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that it has received a notice from Nasdaq indicating that it did not comply with the minimum $50 million market value of listed securities requirement for continued listing set forth in Marketplace Rule 4450(b)(1)(A).
